Physician profile
Steven M Shields
NPI 1548296452
$1,416.85
in general payments reported to CMS, 2019-2025
14 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $126 · 2021: $51.09 · 2022: $194 · 2023: $210 · 2024: $282 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $427.42 | 2022-2025 | Unity, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $363.19 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $129.19 | 2025 | Xdemvy |
| Thea Pharma INC. | $121.43 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $81.88 | 2020-2022 | |
| Harrow Eye, LLC | $48.90 | 2023 | Iheezo |
| Rxsight INC | $47.85 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $44.26 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $40.20 | 2021-2025 | |
| Lumenis, INC | $32.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.37 | 2023 | |
| Coopervision INC. | $22.08 | 2022 | |
| Horizon Therapeutics Plc | $18.05 | 2020 | |
| Aerie Pharmaceuticals, INC. | $16.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.